Table 1.
Baseline characteristics of the two treatment groups.
| Variable | RFA-Sorafenib (n = 103) | RFA (n = 108) | P-value |
|---|---|---|---|
| Age (year) (range) | 54 ± 6 | 53 ± 9 | 0.139 |
| Sex (man/woman) | 86 (83.5%) /17 (16.5%) | 94 (87.0%) /14 (13.0%) | 0.468 |
| HBsAg (+/−) | 95 (92.2%) /8 (7.8%) | 102 (94.4%) /6 (5.6%) | 0.519 |
| Tumor size (cm) (2–3/3–5) | 50 (48.5%) /53 (51.5%) | 51 (47.2%) /57 (52.8%) | 0.848 |
| Tumor number (1/2–3) | 63 (61.2%) /40 (38.8%) | 57 (52.8%) /51 (47.2%) | 0.219 |
| PLT (×109/L) | 102.7 ± 35.6 | 112.0 ± 25.7 | 0.095 |
| ALB (g/L) | 35.5 ± 2.1 | 35.3 ± 3.2 | 0.875 |
| ALT (U/L) | 31.2 ± 6.8 | 29.3 ± 14.6 | 0.101 |
| TBIL (μmol/L) | 9.8 ± 4.7 | 8.9 ± 6.5 | 0.561 |
| Prothrombin activity (%) | 89.6 ± 15.6 | 91.6 ± 13.2 | 0.382 |
| AFP (μg/L) (≤ 400/>400) | 62 (60.2%) /41 (39.8%) | 65 (60.2%) /43 (39.8%) | 0.999 |
| Tumor stage of primary HCC (BCLC A/B) | 84 (81.6%) /19 (18.4%) | 96 (88.9%) /12 (11.1%) | 0.132 |
| Interval of recurrence from initial treatment (year) | 0.649 | ||
| ≤1 | 54 (52.4%) | 60 (55.6%) | |
| >1 | 49 (47.6%) | 48 (44.4%) | |
| Initial hepatic resection type | 0.403 | ||
| One segment | 64 (62.1%) | 61 (56.5%) | |
| More than one segments | 39 (37.9%) | 47 (43.5%) | |
| Antiviral treatment for hepatitis B (yes/no) | 72 (69.9%) /31 (30.1%) | 80 (74.1%) /28 (25.9%) | 0.500 |
| MVI grade (M1/M2) | 59 (57.3%) /44 (42.7%) | 59 (54.6%) /49 (45.4%) | 0.698 |
RFA, radiofrequency ablation; HBsAg, hepatitis B surface antigen; PLT, platelet; ALB, albumin; ALT, alanine aminotransferase; TBIL, total bilirubin; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer group; MVI, microvascular invasion.